Pilot study: Biomarkers for the diagnosis of severe neutrophil inflammatory asthma.

Completed

• Conditions: Severe asthma; 10001708

• Registration Number: NL-OMON42933
• Lead Sponsor: Rijnstate Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

All patients included in this study suffer from severe asthma. When a diagnosis of asthma is confirmed and comorbidities have been addressed, severe asthma is defined as asthma which requires treatment with high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic CS) to prevent it from becoming *uncontrolled* or which remains *uncontrolled* despite this therapy.

Exclusion Criteria

-People suffering from other (chronic, pulmonary or autoimmune) diseases than asthma
-People suffering from an upper or lower respiratory infection within four weeks prior to investigation
-People having an immunodeficiency
-People taking antibiotics (macrolide trial included) or probiotics, four weeks prior to investigation
-People taking oral corticosteroids
-People who smoke.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Th1/Th2/Th17 patterns by analysing cytokine concentrations (Th1: IL-2, TNF,<br /><br>IFN&gamma;; Th2: IL-4, IL-6, IL-10; Th17: IL-17A) in nasal fluid (nasal wash and<br /><br>cotton wool method), saliva and blood.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>n.a.</p><br>